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Microgel Core/Shell Architectures as Targeted Agents for 
Fibrinolysis†  
Purva Kodlekere,*
a,§
 L. Andrew Lyon*
a,b
 
We demonstrate the utility of microgel core/shell structures 
conjugated to fibrin-specific peptides as fibrinolytic agents. 
Poly(N-isopropylmethacrylamide) (pNIPMAm) based microgels 
conjugated to the peptide GPRPFPAC (GPRP) were observed to 
bring about fibrin clot erosion, merely through exploitation of the 
dynamic nature of the clots. These results suggest the potential 
utility of peptide-microgel hybrids in clot disruption and clotting 
modulation. 
Fibrin is a biopolymer that plays a vital role in hemostasis. In 
the occurrence of an injury, fibrinogen, its soluble precursor, is 
enzymatically converted to insoluble fibrin.
1
 A delicate balance 
between the formation of fibrin clots and their dissolution is 
critical for maintaining normal bodily function. Dissolution of 
clots in the body is carried out by the fibrinolytic system, which 
primarily functions via the action of plasmin, through 
activation of its precursor plasminogen. The presence of 
abnormal clots or thrombi leads to physiological states such as 
deep vein thrombosis, atherosclerosis and strokes. In order to 
dissolve such thrombi, plasminogen activators are commonly 
used. However, direct intravenous administration of these 
agents can cause off-target effects and lead to massive 
hemorrhage.
2
 In order to increase the efficacy of these agents 
and reduce off-target effects, a number of target-specific 
delivery agents have been developed.
3-5
 
 Microgels or colloidally stable hydrogel microparticles have 
been utilized for the targeted delivery of therapeutics in the 
past. A number of these studies have involved the utilization of 
ligands or moieties such as proteins or peptides for targeting, 
while using a separate therapeutic agent that is generally 
encapsulated within the microgel matrix.
6-8
 However, there are 
very few reports on the utilization of the therapeutic ability of 
the microgel-ligand conjugates themselves, without a 
supplemental therapeutic agent.
9
 The elimination of variables 
associated with the release of a loaded therapeutic could, in 
principle, result in a more predictable system having a more 
tightly-controlled function. The interactions of colloidal 
particles with pre-formed fibrin clots have been studied 
before.
10, 11
 Additionally, colloids have also been employed as 
imaging agents targeted to fibrin.
12, 13
 
Herein, we present core/shell (C/S) microgels to be used in 
fibrinolysis. The grafting of the fibrin-specific peptide GPRP 
(fibrin knob ‘A’ mimic) to microgels generated conjugates that 
successfully disrupted fibrin clots, presumably via competitive 
binding to the holes ‘a’ in fibrin. These results are promising 
because this system exploits the nature of fibrin as an 
equilibrium polymer
14
 in order to cause clot disruption. The 
occurrence of this disruption in the presence of micromolar 
concentrations of targeting peptide, in the absence of an 
external fibrinolytic agent, demonstrates the novelty and 
potential utility of this system. 
 Particles in three size ranges were synthesized to analyze 
the influence of microgel size on their interactions with fibrin 
clots. We hypothesized that the porosity of fibrin clots would 
lead to differences in particle residence time. The microgels 
were synthesized to have shells with carboxylic acid 
functionalities that later facilitated conjugation of the fibrin-
specific peptides to the microgels.  
 C/S microgels were synthesized using a seed-and-feed 
approach
15
 (Scheme S1, ESI). The synthesis conditions for small 
(S C/S), intermediate (I C/S), and large (L C/S) particles are 
shown in Table 1. Their pH responsivity, sizes and 
polydispersities were analyzed via Dynamic Light Scattering, 
and their spherical profiles were examined by Atomic Force 
Microscopy (Fig. S1 and S2, ESI). Rhodamine was incorporated 
in a polymerizable form (methacryloxyethyl thiocarbamoyl 
rhodamine B, mRhoB) while synthesizing the cores, to aid 
microgel visualization in flow experiments. 
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Table 1. Synthesis conditions for small, intermediate and large Core and C/S microgels 
 
 
Microgel type 
Volume 
of core 
solution 
(mL) 
[NIPMAm] 
(mol%) 
[BIS] 
(mol%) 
[mRhoB] 
(mM) 
[AAc] 
(mol%) 
[SDS] 
(mM) 
[APS] 
(mM) 
RH 
(nm) at 
pH 7* 
S C/S 
Core
α
 - 98 2 0.1 - 8 8 - 
C/S
β
 10 93 2 - 5 2 0.5 102±3 
I C/S 
Core
α
 - 98 2 0.1 - 2 2 - 
C/S
β
 10 93 2 - 5 2 0.5 391±18 
L C/S 
Core
α
 - 98 2 0.1 - 0.5 0.5 - 
C/S
β
 10 93 2 - 5 2 0.5 591±39 
α
[Total monomer] = 140 mM
 
β
[Total monomer] = 50 mM
 
Temperature = 70 °C 
*Measurements in phosphate buffer (50 mM ionic strength) 
 
The development of an effective, microgel-based system for 
targeted delivery of thrombolytic agents to fibrin clots requires 
an investigation into microgel localization in and around clots. 
This is essential to determine the efficacy of microgels for the 
purpose of fibrinolysis, because the rate of clot degradation 
will depend on the region in the clot from where it 
commences, and on the manner of its progression. The 
interplay between microgel size and fibrin clot porosity is thus 
crucial, particularly because microgels are deformable and 
hence can undergo more intricate interactions with the clots 
than comparable hard sphere colloids.
9, 16 
 The porosity of a fibrin clot depends on the clot formation 
conditions.
17-19
 In this study, the concentration of fibrinogen 
used for clot formation was 3 mg/mL, which is close to the 
physiological range of ~2.5 mg/mL; the clots were made using 
1 U/mL thrombin. 
 Scheme 1 represents the experimental set up for the flow 
studies. In a typical experiment, the permeability of fibrin clots 
was first analyzed using Darcy’s law, which relates the average 
interstitial fluid velocity to permeability of the medium. The 
average value of Darcy’s constant ‘k’, i.e. permeability, for all 
clots used in three trials of the experiment was found to be 
(4.027 ± 0.389) × 10
-13
 m
2
, which is in the same range as values 
obtained for similarly prepared fibrin clots in previous 
studies.
11, 20
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Scheme 1. Experimental setup used for examination of perfusion through fibrin clots 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
In every trial, once uniformity in permeabilities was ensured, 
microgel solutions were allowed to flow through the 
respective clots. Following equilibration, eluents were 
collected at 30 min intervals (60 min, if necessary for collection 
of sufficient eluent for analysis), and were analyzed based on 
the fluorescence of mRhoB at λex = 540 nm and λem = 575 nm. 
All fluorescence values were normalized to those of the 
respective (S C/S, I C/S, or L C/S) 0.1 mg/mL reservoir solutions. 
The results obtained from three trials are presented in Fig. 1. 
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Figure 1. Eluents collected at specific time points following 
flow of microgel solutions through fibrin clots demonstrated 
differential microgel-clot interactions based on microgel size. 
Minimal, strong and no interactions were shown by S C/S, I C/S 
and L C/S microgels, respectively, owing to their size relative to 
clot porosity. 
 
 The flow studies revealed differences in microgel passage 
and residence within fibrin clots based on microgel 
dimensions. S C/S microgels were observed to pass through 
the clots easily, appearing in the eluent almost immediately. 
This suggests that these particles had minimal interactions 
with the clot, possibly due to their diameters being 
significantly smaller than the average pore size of the clot. I 
C/S microgels traversed through the clot slower than the S C/S 
microgels, appearing in the eluent only beyond the 1 h time 
point and in seemingly smaller numbers. This suggests that 
their dimensions may be in the range of the average pore size 
of fibrin clots formed under the aforementioned conditions. 
Thus, I C/S microgels appear to interact strongly with clot 
fibers. L C/S microgels were unable to penetrate the clot and 
did not appear in the eluent in the 5 h time frame of the 
experiment. Instead, these microgels concentrated at the front 
interface of the clot, forming a macroscopically visible 
boundary (visualized via the color of mRhoB). Conjugates of 
these microgels with fibrin-specific ligands could constitute a 
toolbox for targeting clots of different architectures. S C/S 
microgels could be utilized for facilitating fibrinolysis of dense 
clots with small pore sizes, due to their ability to target the 
interior regions of such clots. L C/S microgels on the other 
hand, would be better suited for initiating fibrinolysis at the 
surfaces of such clots, or in the internal regions of clots with 
larger pore sizes. 
 Keeping the above results in mind, fibrin specificity was 
imparted to the L C/S microgels by conjugating peptide 
mimics of fibrin knobs ‘A’ and ‘B’ with amino acid 
sequences GPRPFPAC (GPRP) and AHRPYAAC (AHRP), 
respectively. During the polymerization of fibrinogen, the 
fibrinopeptides in the center of the molecule are cleaved by 
the proteolytic action of thrombin. This leads to the 
generation of ‘free’ knobs ‘A’ and ‘B’, which specifically 
interact with the holes ‘a’ and ‘b’ present at the ends of the 
fibrinogen molecules, eventually forming fibrin.
1
 Exposed 
holes ‘a’ and ‘b’ are present in the fibrin structure even 
after polymerization. Their presence, and the specific A:a 
and B:b knob:hole interactions have been exploited in this 
study. The aforementioned peptide mimics and other 
similar sequences have been studied for their fibrin 
specificity in the past.
21, 22
 A control peptide GPSP 
(GPSPFPAC) was also microgel conjugated to investigate 
the impact of a non-binding peptide. This led to the 
generation of L C/S-GPRP, L C/S-GPSP and L C/S-AHRP 
conjugates. The purified microgel-peptide conjugates were 
then used in a flow study set up similar to the one 
represented in Scheme 1. 
 The flow studies were performed with fibrin clots made 
using 2 mg/mL fibrinogen and 1 U/mL thrombin. Prior to 
administering the flow of microgel-peptide conjugates 
through the clots, permeability studies were conducted on 
the clots to ensure uniformity. The Darcy constants for 
trials 1 and 2 represented in Fig. 2 were calculated to be 
(6.3 ± 0.18) × 10
-13
 m
2
 and (8.17 ± 0.30) × 10
-13
 m
2
, 
respectively. Following this, the buffer in the reservoirs was 
replaced with solutions of L C/S, L C/S-GPRP, L C/S-GPSP 
and L C/S-AHRP microgels, all at concentrations of 0.1 
mg/mL. The clots were allowed to equilibrate for 10 min, 
after which flow rates of the microgel solutions through the 
clots were measured at 10 min intervals. The results of 
these measurements are presented in Fig. 2. 
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Figure 2. Trial 1 (A) and trial 2 (B) for flow rate measurements of microgel solutions through fibrin clots. Gray lines indicate flow 
rate of 1X HEPES buffer through the fibrin clots. Pictures of clots after passage of L C/S (C), L C/S-GPSP (D), L C/S-AHRP (E) and L 
C/S-GPRP (F) solutions for 100 min, taken during trial 1. Red arrows indicate extent of microgel passage through clots, bringing 
about partial (D, E) or complete (F) clot disruption. 
 
 
 Flow rate measurements over time and pictures of clots 
taken revealed an initial gradual increase in the flow rates of 
the solutions, followed by the complete disruption of fibrin 
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clots by L C/S-GPRP microgels over the course of the 
experiment (Fig. 2A, B, F). The commencement of disruption is 
at the time point where the increase in flow rate is appreciably 
higher than that of passage of HEPES buffer through the fibrin 
clot. Beyond this point, there is a dramatic increase in flow 
rate signaling complete clot disruption. This progression can 
also be observed in Supplementary Movie M1, obtained 
through a time lapse recording. Additionally, it can be followed 
via a decrease in the size of the clot, from 1.50 cm at the 
beginning of the experiment to 1.32 cm, 1.20 cm, 1.05 cm, 
0.85 cm and 0.53 cm corresponding to the 20 min, 40 min, 60 
min, 80 min and 100 min time points respectively. Fig. 2C 
demonstrates the integrity of the fibrin clot subsequent to 
flow of the L C/S microgel solution through it. This can also be 
witnessed quantitatively via the consistent values of flow rate 
(Fig. 2A, B). These  
 
 
observations allow the elimination of shear stress as a factor 
involved in the clot disruption. Therefore, the fibrinolysis can 
be accounted for primarily by the interactions of the L C/S-
GPRP microgels with the clots, and can be explained in the 
following manner. 
 It has been assumed for some time that fibrin clot 
formation is irreversible and that clot disruption can occur only 
in the presence of the active enzyme plasmin or under non-
physiological conditions. The presence of the tetrapeptide 
GPRP (tGPRP) and PEGylated GPRP during polymerization has 
been known to inhibit polymer formation through competition 
with the knobs ‘A’ for interactions with the complementary 
holes.
22, 23
 However, after clot formation, the effect of such 
peptides on fibrin has only been studied briefly. In 2012, 
Chernysh et al. demonstrated that fibrin clots behave as 
equilibrium polymers.
14
 They hypothesized that fibrin 
monomers and/or oligomers continually dissociate and 
associate with the formed fibers. Bale et al. observed a 
decrease in storage moduli of fibrin clots when 5.8 mM tGPRP 
solution was diffused into them, eventually leading to clot 
liquefaction after two days.
24
 It is worthwhile to note that the 
clots utilized in both these studies were formed under 
different conditions. Nevertheless, the dissolution of the clots 
observed by L C/S-GPRP microgel conjugates can be attributed 
to similar phenomena. The presence of deformable microgels 
with multivalent surface display of peptides presumably 
increases the probability of adjacent, dissociated knob:hole 
junctions being simultaneously occupied by GPRP moieties on 
the microgels, leading to an enhanced effect. Based on the 
theoretical moles of AAc in the microgels, and assuming 100% 
efficiency of peptide conjugation, the upper limit of GPRP 
concentration in a microgel-peptide conjugate solution is in 
the micromolar range. This is at least two orders of magnitude 
below the free GPRP concentrations used in the 
aforementioned studies. Additionally, complete clot disruption 
is observed to take place in less than 3 h from the beginning of 
the flow experiment. This further suggests the importance of 
multivalency in the microgel approach. The difference in 
disruption time seen in the two trials may be explained on the 
basis of the sensitivity of this technique to small variations in 
clot permeabilities. L C/S-AHRP and L C/S-GPSP microgels are 
also seen to increase flow rate of solution through the clots, 
indicating partial clot dissolution (Fig. 2E, D respectively). 
Complete dissolution was not observed in either of these cases 
within the time period of the experiment and additional 
experiments need to be conducted in order to study these 
processes in detail over a longer time frame. However, partial 
dissolution may be attributed to non-specific interactions, 
weak AHRP:knob ‘B’ interactions,
21, 22
 and similarity in GPRP 
and GPSP peptide sequences. 
 To summarize, we have developed C/S microgels with the 
potential to be used as fibrinolytic agents. Flow studies 
revealed size-based differential residence of these microgels in 
fibrin clots. Finally, we demonstrated that conjugation of knob 
‘A’ peptide mimics to the L C/S microgels generated constructs 
capable of disrupting fibrin clots presumably through 
competition with the knobs ‘A’ on fibrin. This competition was 
for intermolecular interactions with the holes ‘a’, generated 
during equilibrium dissociation and association of monomers 
and/or oligomers. The multivalent display of GPRP peptides on 
microgels likely plays an important role in this disruption, 
leading to a faster rate of clot dissolution, at a lower overall 
concentration of peptide in the dispersion, in comparison to 
previous studies. These constructs thus have the ability to 
target and dissolve fibrin clots. Moreover, they also have the 
potential of being loaded with relevant imaging agents for 
visualization of fibrin clots, or with supplemental thrombolytic 
agents (proof of concept studies done with positively charged 
Green Fluorescent Protein, Fig. S3 and S4, ESI), with possible 
triggered, targeted release at the site of the clots, to facilitate 
an even faster rate of fibrinolysis. 
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EXPERIMENTAL METHODS 
 Materials. All materials were purchased from Sigma-Aldrich unless specified otherwise. 
The primary monomer N-isopropylmethacrylamide (NIPMAm) was purified via recrystallization 
from n-hexane (J.T. Baker). The following were all used as received: crosslinker  N,N′-
methylenebis(acrylamide) (BIS), comonomer used for shell synthesis acrylic acid (AAc, Fluka), 
methacryloxyethyl thiocarbamoyl rhodamine B (mRhoB, Poly Fluor 570, Polysciences Inc.), 
CaCl2, KCl, NaCl, anionic initiator ammonium persulfate (APS), buffer preparation materials 
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sodium dihydrogen phosphate, N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) 
(HEPES), 4-morpholineethanesulfonic acid (MES) and formic acid (EMD Millipore), 3-
aminopropyltrimethoxysilane (APTMS) for substrate functionalization for AFM imaging, 
coupling reagents N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and N-
hydroxysulfosuccinimide sodium salt (NHSS), 2-maleimidoethylamine trifluoroacetate salt 
(AEM), human fibrinogen (FIB3, Enzyme Research Laboratories), human α-thrombin (Enzyme 
Research Laboratories, HT 1002a), peptides from GenScript GPRPFPAC (GPRP), GPSPFPAC 
(GPSP) and AHRPYAAC (AHRP), ethanol, isopropanol and acetone. The solutions were 
prepared using distilled water, deionized to a resistance of 18 MΩ (Barnstead E-Pure system). 
Solutions were filtered through a 0.2 µm Acrodisc syringe filter before use. 
 
 Microgel core synthesis. Microgel cores were synthesized by free radical precipitation 
polymerization. In a typical synthesis, NIPMAm and BIS in molar compositions of 98% and 2% 
respectively were dissolved in 48.5 mL distilled, deionized water, to a total monomer 
concentration of 140 mM, along with SDS at the relevant concentration (refer to Table 1). The 
resulting solution was filtered through a 0.8 µm Acrodisc syringe filter and introduced into a 100 
mL three necked, round bottom flask along with a magnetic stirrer. The flask was fitted with a 
thermometer, condenser and N2 inlet and introduced into an oil bath, which was heated at 100 
°C/h. Stirring was kept constant at 400 rpm and the solution was purged with N2. Once the 
temperature was stable at 70 °C, 0.5 mL of a solution of mRhoB in DMSO (final concentration 
0.1 mM) was introduced into the flask, following which 1 mL of the initiator APS was added 
after filtration through a 0.2 µm Acrodisc syringe filter. The reaction was allowed to proceed for 
4 h under a N2 blanket, after which it was cooled down to room temperature. The solution was 
then filtered through glass wool. 
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  Microgel shell synthesis. Core/shell microgels were synthesized using a ‘seed-and-feed’ 
method. The shell monomer solution was prepared by dissolving NIPMAm, BIS and AAc in 
molar feed ratios of 93%, 2% and 5% respectively, in 39.5 mL distilled, deionized water, to a 
total monomer concentration of 50 mM. Following the addition of SDS (final concentration: 2 
mM), the resulting solution was filtered through a 0.8 µm Acrodisc syringe filter. This monomer 
shell solution along with 10 mL of the respective core solution was heated to 70 °C in a manner 
similar to the core synthesis and was initiated with 0.5 mL APS once temperature stability was 
achieved. The synthesis was then allowed to proceed for 4 h under a N2 blanket, with constant 
stirring at 400 rpm. It was then cooled down to room temperature and the solution was filtered 
through glass wool. The microgels were then purified by pelleting via ultracentrifugation at 
104000–417000 × g for 20–70 min, depending on the microgel type. Every run of 
ultracentrifugation was followed by removal of the supernatant and resuspension in DI water. 
This process was repeated six times, after which the microgels were lyophilized prior to 
characterization. 
 
Dynamic Light Scattering. Hydrodynamic radii (RH) of the microgels were determined 
via dynamic light scattering (DLS, DynaPro, Protein Solutions). Measurements were performed 
in the following buffers: pH 7 phosphate (50 mM ionic strength), pH 7.4 HEPES (6 mM ionic 
strength), pH 3 formate (50 mM ionic strength) and pH 3 formate (6 mM ionic strength). 
Microgel samples in the respective buffers were thermally equilibrated for 20 min, following 
which scattering intensity fluctuations based on Brownian motion of the microgels were detected 
at a scattering angle of 90°. Twenty-five (25) acquisitions of 20 s each were obtained. These were 
used to generate intensity-time correlation functions, and cumulants analysis was used in order to 
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attain diffusion coefficients. The Stokes-Einstein equation was then utilized to calculate RH 
values. This procedure was repeated 3 more times on the same sample in order to generate a total 
of 100 RH values for each microgel sample and averages of these values along with standard 
deviations are presented. 
 
 Atomic Force Microscopy. Atomic Force Microscopy (AFM) was performed using an 
MFP-3D AFM (Asylum Research). Images were acquired in air and under ambient conditions in 
the tapping mode, using pyramidal cantilevers (Nanoworld, Force Constant 42 N/m) made of 
heavily doped silicon. Image processing was performed using software written in an IgorPro 
environment (Wavemetrics, Inc.) 
Samples were prepared on 22 mm × 22 mm glass coverslips (VWR). The coverslips were 
cleaned by sequential sonication in Alconox solution, DI water, acetone, 95% ethanol, and 
isopropanol for 20 min each. They were then functionalized in a 1% (v/v) APTMS/absolute 
ethanol solution on a shaker table for 2 h, following which they were washed with DI water. The 
microgel solutions prepared in phosphate buffer (pH 7, 50 mM ionic strength) were then used for 
submonolayer deposition onto the glass substrates by centrifugation at 2250 × g for 10–25 min 
(depending on the microgel type) at 25 °C using a plate rotor. The coverslips were rinsed well 
with DI water and dried with nitrogen before imaging. 
 
 Production and purification of +6 GFP. Plasmids with genes encoding for +6 GFP
1
 
from Prof. David Liu’s research group (Howard Hughes Medical Institute, Harvard University) 
were used for transformation of E.coli, following which the production and purification of the 
protein was performed in a manner similar to that utilized by Cronican et al.
2
 with slight 
modifications. Briefly, transformed E.coli were grown to an optical density of 0.6 in LB broth 
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(Lennox, Alfa Aesar), following which they were induced with 1 mM IPTG (Isopropyl β-D-
thiogalactopyranoside, ThermoFisher) at 30 °C for 4 h. The cells were then harvested and 
preserved as pellets at −80 °C. These pellets were thawed in a solution of 1X PBS with 2 M NaCl 
and sonication was employed to lyse them. Following centrifugation at 10000 × g for 8 min, the 
supernatant was mixed with Ni-NTA resin (Fisher Scientific) for 30 min at 4 °C. The removal of 
resin by centrifugation was followed by multiple washes with 2 M NaCl and 20 mM imidazole 
(Fisher Scientific) and then a 2 M NaCl + 500 mM imidazole solution was used for detachment 
of the protein from the resin. Dialysis against 1X PBS for 18 h at 4 °C was then carried out, 
followed by SDS-PAGE staining with Simply Blue (ThermoFisher). 
 
 +6 GFP encapsulation studies. Lyophilized core/shell microgels were weighed and 
resuspended in 0.20 µM +6 GFP solution in the respective buffer (6 mM ionic strength HEPES or 
150 mM ionic strength HEPES). After a 20 h equilibration, the microgel solutions were 
centrifuged at 104000–417000 × g for 20–70 min, depending on the microgel type. The 
supernatants were analyzed for presence of +6 GFP by fluorescence measurements at λex = 475 
nm and λem = 520 nm. Normalization was performed against stock +6 GFP solutions in the 
respective buffer conditions. 
 
 Fibrin clot formation. Solutions of fibrinogen (13.51 mg/mL) and thrombin (10 U/mL) 
were thawed to room temperature. The fibrinogen was mixed with CaCl2 (final concentration 5 
mM), HEPES (final concentration 25 mM HEPES, 150 mM NaCl) and DI water, following 
which clot formation was initiated by introducing thrombin at a final concentration of 1 U/mL. 
The final concentration of fibrinogen was either 3 mg/mL (size-based localization studies) or 2 
mg/mL (clot disruption studies). The clots were formed in plastic capillary tubes (Globe 
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Scientific, Inc., I.D. = 0.85 mm), and were allowed to polymerize overnight in a humid 
environment, to avoid abnormalities due to drying. For the perfusion experiments, they were cut 
into 1.5 cm pieces for utilization with each sample solution. 
 
 Permeability measurements and perfusion studies. Flow studies were performed using 
the experimental setup represented in Scheme 1. 1X HEPES buffer (same as that used for clot 
preparation) was first perfused through the 1.5 cm clots. Following 15 min equilibration, flow 
rates of buffer post traversal through the fibrin clots were measured for 3–5 min (depending on 
the clot formation conditions), from a solution reservoir height of 18 in. Three measurements 
were made for every clot and clot permeability values were calculated using Darcy’s law, 
Q =
k
μ
A	
ΔP
L
 
where Q is the volumetric flow (m
3
/s), k is Darcy’s constant or the Darcy permeability (m
2
), µ is 
the liquid viscosity (kg/ms), A is the cross-sectional area of the clot (m
2
), ΔP is the pressure 
gradient across the clot (kg/ms
2
) and L is the length of the cylindrical clot (m). 
 Following confirmation of consistency in clot permeabilities, buffer solutions in the 
reservoirs were replaced by microgel solutions at a concentration of 0.1 mg/mL and these were 
allowed to flow through the clots. After equilibration for 15 min, eluent collection was begun and 
was performed at 30 min intervals. The eluents were analyzed for their fluorescence using a plate 
reader (Infinite® 200 PRO NanoQuant™, Tecan Group LTD., San Jose, CA) at excitation and 
emission wavelengths of 540 nm and 575 nm, respectively. Following background corrections for 
the buffer, fluorescence intensities normalized to those of the respective reservoir microgel 
solutions (0.1 mg/mL) were calculated. Three trials were performed and values of normalized 
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fluorescence intensities are presented as averages of values obtained at the respective time points 
from these trials. Standard deviations were also obtained from these values and are presented. 
 
 Conjugation of peptides to microgels. L C/S microgels were divided into three sections 
and resuspended in MES buffer (20 mM ionic strength). They were then conjugated to AEM 
through carbodiimide coupling, using a 2X molar excess of EDC and NHSS and a 1:1 –
COOH:AEM molar ratio, based on the theoretical number of AAc moieties incorporated in the 
microgel shells. This conjugation was allowed to proceed for 2 h, following which dialyses for all 
three solutions were performed against MES buffer for 15 h. The MES buffer was then replaced 
with phosphate buffer (pH 7, 140 mM ionic strength) and following equilibration for ~8 h, 
peptide conjugations to GPRP, GPSP and AHRP (1:0.2 molar ratio of theoretical –
COOH:peptide) were performed overnight through thiol-maleimide coupling. The resulting 
solutions were dialyzed against DI water for one week and placed on a shaker for homogeneity. 
A small portion of each solution was lyophilized in order to determine concentration of the stock 
solutions. 
 
 Clot disruption studies under flow. Clot disruption analyses were performed using a 
setup similar to the one utilized for permeability measurements. 1.5 cm fibrin clots were first 
analyzed for their consistency in permeability by conducting flow rate measurements using 1X 
HEPES buffer. The Darcy constant k was determined for each clot, following which reservoir 
buffer solutions (at an 18 in height) were replaced with the respective peptide-conjugated L C/S 
microgel solutions (0.1 mg/mL). After equilibration for 10 min, flow rate measurements (3 min 
each) were conducted for each microgel solution, after passage through the clot. This was 
repeated every 10 min until clot disruption was observed. Pictures of clots were also taken at 
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various time points during the experiment. Two separate trials were performed and the results 
from these are presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme S1. General representation of a two-step core (A) and core/shell (B) microgel synthesis 
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Microgel characterization 
  
 
 
 
 
 
Figure S1. DLS measurements performed on S C/S (A), I C/S (B) and L C/S (C) microgels generated RH 
values that demonstrated a slightly greater magnitude of pH responsivity at 6 mM ionic strength, than at 
50 mM ionic strength, due to partial screening of charges in the presence of a higher concentration of ionic 
species in solution.  
 
 
 
   
 
 
 
 
 
 
Figure S2. AFM height traces of S C/S, I C/S and L C/S microgels deposited on APTMS-functionalized 
glass by centrifugal deposition at 2250 × g for 10–25 min at 25 °C, depending on the microgel type. 
Particles in all three size ranges were spherical and the differences in microgel size were evident from the 
images and height profiles. 
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Production of +6 GFP 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. SDS-PAGE of purified +6 GFP. Based on the molecular weight standards (A), the bands 
represent the presence of +6 GFP (molecular weight of GFP is 27 kDa) 
3
. B and C represent the +6 GFP 
solutions before and after dialysis, respectively. 
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Analysis of +6 GFP encapsulation in core/shell microgels 
 
 
 
 
 
 
 
 
 
 
Figure S4. Analysis of encapsulation of +6 GFP by S C/C, I C/S and L C/S microgels. 
Fluorescence intensities of supernatants were normalized to those of +6 GFP solutions in the 
respective buffers. Charge screening at higher (150 mM) ionic strength was found to be effective 
in causing differential encapsulation (Values presented as averages of 3 measurements on single 
samples, error bars represent standard deviations in these three values). 
 
 
 This analysis revealed that the size of +6 GFP (~ 27 kDa) is in a range that allows passage 
into microgels with the crosslinking density used in these experiments. Thus, encapsulation of 
other proteins with dimensions similar to +6 GFP into microgels may be feasible. Additionally, 
these results also indicate that charge interactions play an important role in this encapsulation. 
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Figure S2. AFM height traces of S C/S, I C/S and L C/S microgels deposited on APTMS-functionalized glass 
by centrifugal deposition at 2250 × g for 10–25 min at 25 °C, depending on the microgel type. Particles in 
all three size ranges were spherical and the differences in microgel size were evident from the images and 
height profiles.  
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